Blood levels of a tau protein fragment were significantly higher in former football players who were found after death to have advanced chronic traumatic encephalopathy, Boston University researchers reported Thursday, Nov. 19. The researchers say it is the first time CTE has been detected with only a blood test. Today the disease can be confirmed only by examining the brain after death.
The test isn't ready for patients. It is not approved by the Food and Drug Administration, it is not available to the public, and it missed early-stage disease. The BU team's announcement says people should not try to use it to make decisions about CTE until larger studies are done.
What the study found

The BU and Banner Health team, publishing in JAMA, looked at blood drawn from 21 former American football players while they were alive, all of whom later donated their brains to the BU CTE Center for study after death. At autopsy, 18 had CTE. Three did not. Sixteen of the 18 had high-stage disease, McKee stage 3 or 4.
The researchers measured eMTBR-tau, a fragment of tau, which is the protein that forms tangles in the brain in both CTE and Alzheimer's disease. Blood levels were significantly higher in the players with high-stage CTE than in players whose CTE was early or absent. Early disease didn't register.
Advanced disease was most common among the former pros. Eleven of the 12 had high-stage CTE, compared with four of seven college players and one of two who played only in high school.
"We are still in the discovery phase and it's a small sample size," said Michael Alosco, co-director of clinical research at the BU CTE Center. If larger studies confirm it, he said, the test could detect CTE "with a high level of accuracy and open the doors to clinical trials and treatment."
A second team found the same signal
A separate group at Washington University School of Medicine in St. Louis reached a similar result with a different method, in a JAMA study published Nov. 13. That team was studying a related fragment, eMTBR-tau243, as an Alzheimer's marker across 229 participants. One participant had a high blood level but no Alzheimer's at autopsy. That person's brain showed advanced CTE. The team went on to check samples from 11 people whose CTE was confirmed at autopsy. Their levels beat those of healthy volunteers and climbed as the disease got worse.
Because two teams found the marker in different patients using different lab methods, the BU researchers say the link now has strong support.
Why it can't diagnose anyone yet

Both teams say larger studies are needed. The samples are small. Very few people with early CTE were included, and the BU study had no age-matched comparison group. Alzheimer's disease also pushes the marker up, and the two conditions often appear together. In the BU study, the five people with both diseases had the highest levels of all.
That means a positive result alone can't separate the two diseases. WashU co-author Chihiro Sato described how it might eventually be used. In someone with a history of repeated head injuries who tests negative for Alzheimer's, a high level "might be CTE."
WashU has licensed its version of the test to C2N Diagnostics, a startup that already sells an FDA-cleared blood test used in diagnosing Alzheimer's. For CTE, it is unvalidated.
For now, BU advises anyone worried about their brain health to get evaluated by a specialist in neurodegenerative disease. BU says its studies are still enrolling, and former players who want to take part can join the Concussion & CTE Foundation research registry.














